Circulating thymulin and thymosin-alpha 1 activity in pediatric acquired immune deficiency syndrome: in vivo and in vitro studies.
Rubinstein. A A; Novick. B E BE; Sicklick. M J MJ; Bernstein. L J LJ; Incefy. G S GS; Naylor. P H PH; Goldstein. A L AL
Key Findings
- Low plasma thymulin levels appeared before T‑cell deficits in pediatric AIDS patients
- Serum thymosin‑alpha‑1 levels were elevated in these patients
- Treatment with thymosin fraction 5 produced only brief clinical and immune improvements
Practical Outcomes
- For biohackers focused on healthy longevity, this study offers little actionable guidance. The findings are specific to children with AIDS and show only temporary benefits from thymosin treatment, so it doesn’t support a practical protocol for performance or anti‑aging use.
Summary
In kids with AIDS, a hormone called thymulin was low before their immune cells dropped, while another molecule, thymosin‑alpha‑1, was unusually high. Giving a thymosin‑based drug helped a little but only for a short time.
Abstract
Twenty-five children with acquired immune deficiency syndrome (AIDS) or AIDS-related complex had a characteristic pattern of T cell deficiency. Abnormally low plasma thymulin levels preceded the development of peripheral blood T cell abnormalities. In contrast to patients with congenital T cell deficiencies, our patients had elevated serum levels of thymosin-alpha 1. Treatment with thymosin fraction 5 in three children with AIDS resulted in only transient clinical and immunologic improvement.
Study Information
pubmed
1986
10.1016/s0022-3476(86)80111-1